This is the first attempt to combine the exploration of biomarkers of depression and evaluating the effect of citalopram by a metabolomics method, and then use the method to access the depression status according to the changed metabolome.
No takes yet. Share an insight, caveat, or question.
Yu et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: